Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $1.14M | $3.46M | $3.15M | $14.9M | $1.25M | $5.49M | $9.29M | $27.5M |
| Revenue growth | — | — | 202.7% | -8.8% | 373.7% | -91.7% | 341.0% | 69.2% | 195.7% |
| Operating income | -$23.2M | -$38.7M | -$36.8M | -$45.0M | -$43.7M | -$53.2M | -$52.1M | -$41.5M | -$26.6M |
| Operating margin | — | -3386.7% | -1063.2% | -1428.0% | -292.6% | -4275.1% | -949.9% | -446.9% | -96.7% |
| Net income | -$23.2M | -$39.0M | -$36.7M | -$44.8M | -$44.2M | -$53.0M | -$50.7M | -$40.7M | -$26.6M |
| Net margin | — | -3411.5% | -1061.2% | -1419.8% | -295.6% | -4257.8% | -924.1% | -438.0% | -96.9% |
| EPS (diluted) | -$2.16 | -$1.94 | -$1.66 | -$1.56 | -$1.41 | -$1.49 | -$1.11 | -$0.72 | -$0.28 |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$12.1M | -$26.4M | -$30.8M | -$32.5M | -$38.8M | -$41.8M | -$40.0M | -$36.3M | -$21.7M |
| Capital expenditures | $1.03M | $1.85M | $46.4K | $595K | $913K | $171K | $0.00 | $66.0K | $177K |
| Free cash flow | -$13.2M | -$28.3M | -$30.8M | -$33.1M | -$39.8M | -$42.0M | -$40.0M | -$36.4M | -$21.9M |
| Share buybacks | — | — | $91.0K | $271K | $750K | $200K | $0.00 | — | — |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | — | $20.8M | $44.3M | $74.9M | $64.4M | $51.6M | $48.5M | $22.5M | $27.1M |
| Total assets | $67.0M | $45.4M | $71.6M | $99.5M | $83.4M | $91.3M | $61.5M | $32.2M | $42.2M |
| Total liabilities | $5.35M | $11.4M | $17.0M | $20.6M | $17.9M | $25.6M | $24.4M | $14.7M | $15.8M |
| Long-term debt | — | — | — | — | $0.00 | $8.04M | $4.20M | $0.00 | — |
| Shareholders' equity | $61.6M | $34.0M | $54.6M | $78.9M | $65.5M | $65.7M | $37.1M | $17.5M | $26.4M |
| Retained earnings | -$32.8M | -$71.8M | -$109M | -$153M | -$197M | -$250M | -$301M | -$342M | -$368M |
| Shares (wtd avg diluted) | 19.5M | 20.7M | 26.6M | 30.4M | 31.3M | 35.6M | 45.8M | 56.3M | 94.7M |
Every figure is extracted from Cue Biopharma, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.